flaggen en

flaggen en flaggen dt flaggen it   flaggen es flaggen fr   flaggen he   flaggen pl   flaggen jp   flaggen ar   flaggen inflaggen gr

flaggen en

flaggen en

EMAGood news for GIST patients in the EU: On 16 September 2021, the CHMP (Committee for Medicinal Products for Human Use) of EMA has issued a positive opinion on granting the marketing approval for ripretinib (Qinlock®) for patients with advanced gastrointestinal stromal tumours (GIST) who already received three or more kinase inhibitors prior. Read EMA’s press release here: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/qinlock